ExpreS2ion Biotech – Presentation of Q1 2026 Interim Report
You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.
ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
2025 was a transition year in which ExpreS2ion moved from preclinical work to clinical execution while tightening its cost base. Operating income rose 56% to SEK 12.2m and operating costs declined 25% to SEK -56.5m, bringing the operating loss to SEK -44.3m (SEK -67.7m). Operationally, the company dosed the first patient in the Phase I trial of ES2B-C001 in June, reported initial immunogenicity data in September, received DSMB clearance to advance to dose cohort 2 in December,This sets up 2026 as the year in which Phase Ia dose escalation (mid-2026) and the Phase Ib expansion cohort (late-2026) represent the key value-inflection points.
Since the Q4 report, ExpreS2ion has announced a fully pre-emptive rights issue of approximately SEK 53m (incl. TO13 warrants), with the subscription period running 16–30 April 2026. Updated Phase I immunogenicity data and DSMB recommendation of escalation to the 450-µg dose and expansion of the current cohort. Eight of nine evaluable patients across the 50-µg and 150-µg dose cohorts developed a drug-specific anti-HER2 immune response, with titers remaining elevated at later follow-up visits and, in the first treated patient, sustained for approximately five months after the final dose. Positive Phase Ia data from the University of Oxford's BIO-002 malaria, adding independent human clinical validation to its platform.
In addition to the Q1 2026 financial results, focus is expected to be on next data readouts from the Phase I trial with ES2B-C001, the final outcome of the rights issue, the implications of the BIO-002 data for the ExpreS2 platform, and updates on the Nipah programme.
ExpreS2ion Biotech is a vaccine company with a clinically validated protein expression platform (ExpreS2™) and a focused pipeline of vaccine assets. Its lead program, ES2B-C001, is a HER2-targeted therapeutic breast cancer vaccine in Phase I, and the primary near-term value driver. The ExpreS2™ platform supports partnered programs in malaria, influenza, and Nipah virus, generating value through licensing, milestones, and royalties.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotech for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 09.04, 24/04/2026.
